Pulse Biosciences (PLSE) Debt to Equity (2021 - 2023)
Pulse Biosciences' quarterly Debt to Equity came in at -$6.09 in Q1 2023, up 78.93% quarter-over-quarter from -$28.91 in Q4 2022.
Pulse Biosciences has reported Debt to Equity for 3 years, with the latest figure at -$6.09 in Q1 2023.
- For the quarter ending Q1 2023, Debt to Equity changed N/A year-over-year to -$6.09; the trailing twelve-month figure through Mar 2023 stood at -$6.09 (changed N/A YoY), and the FY2022 full-year result was -$28.91, changed N/A from the prior year.
- Debt to Equity for Q1 2023 stood at -$6.09, up from -$28.91 in the prior quarter.
- The five-year high for Debt to Equity was $10.5 in Q3 2022, with the low at -$28.91 in Q4 2022.
- Average Debt to Equity over 3 years is -$5.62, with a median of -$2.04 recorded in 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 156.17 Bn | 151.78 Bn | 1.83 Bn | - |
| 2 | Becton Dickinson | 41.51 Bn | 40.49 Bn | 2.15 Bn | 0.72 |
| 3 | Resmed | 30.43 Bn | 28.77 Bn | 890.98 Mn | 0.04 |
| 4 | West Pharmaceutical Services | 22.78 Bn | 22.26 Bn | 296.40 Mn | 0.07 |
| 5 | Solventum | 13.39 Bn | 13.39 Bn | 1.10 Bn | 1.02 |
| 6 | Cooper Companies | 12.33 Bn | 12.20 Bn | 695.20 Mn | 0.30 |
| 7 | Align Technology | 11.65 Bn | 10.59 Bn | 736.59 Mn | - |
| 8 | Baxter International | 9.81 Bn | 7.77 Bn | 891.00 Mn | 1.57 |
| 9 | Aptargroup | 7.39 Bn | 7.19 Bn | 351.91 Mn | 0.45 |
| 10 | Pulse Biosciences | 1.72 Bn | 1.72 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | -6.09 |
| Dec 31, 2022 | -28.91 |
| Sep 30, 2022 | 10.50 |
| Mar 31, 2021 | 2.01 |